Carregant...
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the causal factors? Can it be avoided?
Natalizumab (Tysabri®) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, three patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with pro...
Guardat en:
| Autors principals: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4157908/ https://ncbi.nlm.nih.gov/pubmed/20697042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2010.161 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|